EpiEndo Pharmaceuticals has received regulatory approval to commence a Phase 2a clinical trial with lead molecule EP395 in COPD (Chronic Obstructive Pulmonary Disease) patients.

EpiEndo Pharmaceuticals has received regulatory and ethics approval to commence a Lipopolysaccharide (LPS) challenge clinical trial with lead molecule EP395.

EpiEndo Pharmaceuticals has completed its Phase I First Time in Human (FTIH) study with EP395 in healthy subjects.

EpiEndo Pharmaceuticals has appointed two new non-executive board members following the departure of Robert Helgason, who stepped down at the Company’s AGM on 26 April 2022.

EpiEndo Pharmaceuticals has expanded its operations with a new laboratory facility in Sweden and new staff hired to key positions.

EpiEndo Pharmaceuticals is pleased to announce the appointment of Stefan Petursson as Chief Financial Officer (CFO), starting 1. April, 2022.

In the January edition of the Nordic Life Science Magazine, the leading life science business magazine in the Nordics there is an article about us.

EpiEndo Pharmaceuticals is an Icelandic clinical stage pharmaceutical company with a unique focus on impairment of epithelial barriers as a common mechanism of many inflammatory conditions such as the airway, gastrointestinal tract and skin.

EpiEndo Pharmaceuticals is a clinical stage pharmaceutical company with a unique focus on impairment of epithelial barriers as a common mechanism of many inflammatory conditions such as the airway, gastrointestinal tract tract and skin.